On May 23, 2025 GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, reported that Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute will present updated clinical and translational data of GV20-0251 monotherapy at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2025 Annual Meeting, taking place in Chicago, IL on May 30- June 3, 2025 (Press release, GV20 Therapeutics, MAY 23, 2025, View Source [SID1234653366]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This presentation at ASCO (Free ASCO Whitepaper) builds on previously presented clinical data of the novel immune checkpoint IGSF8 inhibitor GV20-0251 (Wentzel et al, ESMO (Free ESMO Whitepaper) 2024) and will report updated clinical and translational findings from the monotherapy dose escalation portion of the ongoing Phase 1/2 trial evaluating GV20-0251 in patients with advanced solid tumors resistant to anti-PD(L)1 and other standard therapies (NCT05669430).
GV20-251 is the first clinical stage, AI-designed antibody therapeutic against an AI-predicted target in the clinic.
Presentation details (Abstract 2531):
Title: Preliminary monotherapy efficacy of novel immune checkpoint blockade GV20-0251 (anti-IGSF8) in advanced melanoma patients with primary resistance to anti-PD1
Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster session
Session Date/Time: Monday, June 2, 2025, 1:30 PM – 4:30 PM CDT
Location: Hall A – Posters and Exhibits
Board Number: 178